Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
Following initial presentation of SEASTAR trial data on the novel combination of sacituzumab govitecan plus rucaparib, which was investigated for use in metastatic triple-negative breast cancer and other advanced/metastatic solid tumors (ie, platinum-resistant ovarian cancer, urothelial cancers), at this year’s annual virtual European Society for Medical Oncology (ESMO) meeting, Timothy A. Yap, MBBS, PhD, FRCP, medical director, Institute for Applied Cancer Science, the University of Texas MD Anderson Cancer Center, discusses with The American Journal of Managed Care® the toxicities associated with this treatment and how they were managed in the investigative setting.
Transcript
How do the clinical toxicities from PARP and TOP1 inhibitors affect treatment?
Clinically, PARP inhibitors, such as rucaparib, and TOP1 inhibitors, such as irinotecan, have shown highly synergistic antitumor effects. But as noted in our ESMO presentation, clinical development of this combination has been hampered by overlapping toxicities, and these overlapping toxicities chiefly comprise myelosuppression, gastrointestinal symptoms, and fatigue. This arm of the SEASTAR study was designed to explore whether a targeted tumor delivery of the TOP1 inhibitor irinotecan through the use of sacituzumab govitecan as part of that could actually reduce the systemic toxicity of the combination. And the toxicities we observed in the study were effectively managed through dose modification and or hemopoietic growth factor support, and together with the initial encouraging signals of antitumor activity suggests that further study of this combination is warranted.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More